SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Xin He, G. A. Whitmore, Geok Yan Loo, Marc C. Hochberg, Mei-Ling Ting Lee, A model for time to fracture with a shock stream superimposed on progressive degradation: the Study of Osteoporotic Fractures, Statistics in Medicine, 2015, 34, 4
  2. 2
    Tsuyoshi Sukenari, Motoyuki Horii, Kazuya Ikoma, Masamitsu Kido, Shigeki Hayashi, Yusuke Hara, Tetsuro Yamasaki, Ken-ichi Matsuda, Mitsuhiro Kawata, Toshikazu Kubo, Cortical bone water changes in ovariectomized rats during the early postoperative period: Objective evaluation using sweep imaging with Fourier transform, Journal of Magnetic Resonance Imaging, 2015, 41, 5
  3. 3
    P. Roth, C. Happold, M. Weller, Corticosteroid use in neuro-oncology: an update, Neuro-Oncology Practice, 2015, 2, 1, 6

    CrossRef

  4. 4
    Przemyslaw Marcin Sowa, Martin J. Downes, Louisa G. Gordon, Cost-effectiveness of dual energy X-ray absorptiometry (DXA) plus anti-resorptive treatment in Australian women with breast cancer who receive aromatase inhibitors, Journal of Bone and Mineral Metabolism, 2015,

    CrossRef

  5. 5
    R. A. Overman, M. L. Gourlay, C. L. Deal, J. F. Farley, M. A. Brookhart, J. B. Layton, Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis, Osteoporosis International, 2015,

    CrossRef

  6. 6
    Taiki Sato, Hiroto Hayashi, Masahiro Hiratsuka, Noriyasu Hirasawa, Glucocorticoids decrease the production of glucagon-like peptide-1 at the transcriptional level in intestinal L-cells, Molecular and Cellular Endocrinology, 2015, 406, 60

    CrossRef

  7. 7
    Michael J. Leach, Nicole L. Pratt, Elizabeth E. Roughead, Psychoactive medicine use and the risk of hip fracture in older people: a case-crossover study, Pharmacoepidemiology and Drug Safety, 2015, 24, 5
  8. You have free access to this content8
    Arundathi Jayasena, Navoda Atapattu, Sarath Lekamwasam, Treatment of glucocorticoid-induced low bone mineral density in children: a systematic review, International Journal of Rheumatic Diseases, 2015, 18, 3
  9. 9
    Chamith S. Rajapakse, Mahdieh Bashoor-Zadeh, Cheng Li, Wenli Sun, Alexander C. Wright, Felix W. Wehrli, Volumetric Cortical Bone Porosity Assessment with MR Imaging: Validation and Clinical Feasibility, Radiology, 2015, 141850

    CrossRef

  10. 10
    Karine Briot, Bernard Cortet, Christian Roux, Laurence Fardet, Vered Abitbol, Justine Bacchetta, Daniel Buchon, Françoise Debiais, Pascal Guggenbuhl, Michel Laroche, Erik Legrand, Eric Lespessailles, Christian Marcelli, Georges Weryha, Thierry Thomas, 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis, Joint Bone Spine, 2014, 81, 6, 493

    CrossRef

  11. 11
    Helena Johansson, John A Kanis, Anders Odén, Eugene McCloskey, Roland D Chapurlat, Claus Christiansen, Steve R Cummings, Adolfo Diez-Perez, John A Eisman, Saeko Fujiwara, Claus-C Glüer, David Goltzman, Didier Hans, Kay-Tee Khaw, Marc-Antoine Krieg, Heikki Kröger, Andrea Z LaCroix, Edith Lau, William D Leslie, Dan Mellström, L Joseph Melton, Terence W O'Neill, Julie A Pasco, Jerilynn C Prior, David M Reid, Fernando Rivadeneira, Tjerd van Staa, Noriko Yoshimura, M Carola Zillikens, A Meta-Analysis of the Association of Fracture Risk and Body Mass Index in Women, Journal of Bone and Mineral Research, 2014, 29, 1
  12. 12
    Karine Briot, Bernard Cortet, Christian Roux, Laurence Fardet, Vered Abitbol, Justine Bacchetta, Daniel Buchon, Françoise Debiais, Pascal Guggenbuhl, Michel Laroche, Érik Legrand, Éric Lespessailles, Christian Marcelli, Georges Weryha, Thierry Thomas, Actualisation 2014 des recommandations sur la prévention et le traitement de l’ostéoporose cortico-induite, Revue du Rhumatisme, 2014, 81, 5, 385

    CrossRef

  13. 13
    红军 朱, Analysis of Risk Factors Leading to Osteoporosis Research, Medical Diagnosis, 2014, 04, 02, 15

    CrossRef

  14. 14
    Stinus Hansen, Claire Gudex, Fabian Åhrberg, Kim Brixen, Anne Voss, Bone Geometry, Volumetric Bone Mineral Density, Microarchitecture and Estimated Bone Strength in Caucasian Females with Systemic Lupus Erythematosus. A Cross-Sectional Study Using HR-pQCT, Calcified Tissue International, 2014, 95, 6, 530

    CrossRef

  15. 15
    Georgina M Russell, Stafford L Lightman, Can side effects of steroid treatments be minimized by the temporal aspects of delivery method?, Expert Opinion on Drug Safety, 2014, 13, 11, 1501

    CrossRef

  16. 16
    Herbert James, Ilija Aleksic, Marc Nicolas Bienz, Christopher Pieczonka, Peter Iannotta, David Albala, Neil Mariados, Vladimir Mouraviev, Fred Saad, Comparison of Fracture Risk Assessment Tool Score to Bone Mineral Density for Estimating Fracture Risk in Patients With Advanced Prostate Cancer on Androgen Deprivation Therapy, Urology, 2014, 84, 1, 164

    CrossRef

  17. 17
    K. Ebina, J. Hashimoto, K. Shi, M. Kashii, M. Hirao, H. Yoshikawa, Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients, Osteoporosis International, 2014, 25, 12, 2755

    CrossRef

  18. 18
    Terumasa Ikeda, Kouichi Maruyama, Hiroshi Kaji, Masao Akagi, Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid, Modern Rheumatology, 2014, 24, 4, 671

    CrossRef

  19. 19
    Yuji Kasukawa, Naohisa Miyakoshi, Toshihito Ebina, Toshiaki Aizawa, Michio Hongo, Koji Nozaka, Yoshinori Ishikawa, Hidetomo Saito, Shuichi Chida, Yoichi Shimada, Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis, Journal of Bone and Mineral Metabolism, 2014, 32, 3, 290

    CrossRef

  20. 20
    Young-Jee Jeon, Ji Wan Kim, Joo-Sung Park, Factors Associated with the Treatment of Osteoporosis in Korean Postmenopausal Women, Women & Health, 2014, 54, 1, 48

    CrossRef

  21. 21
    René Rizzoli, Emmanuel Biver, Glucocorticoid-induced osteoporosis: who to treat with what agent?, Nature Reviews Rheumatology, 2014, 11, 2, 98

    CrossRef

  22. 22
    Holger Henneicke, Sylvia J. Gasparini, Tara C. Brennan-Speranza, Hong Zhou, Markus J. Seibel, Glucocorticoids and bone: local effects and systemic implications, Trends in Endocrinology & Metabolism, 2014, 25, 4, 197

    CrossRef

  23. 23
    Long Wang, Jing Fan, Yan-Shui Lin, Yun-Shan Guo, Bo Gao, Qi-Yue� Shi, Bo-Yuan Wei, Li Chen, Liu Yang, Jian Liu, Zhuo-Jing Luo, Glucocorticoids induce autophagy in rat bone marrow mesenchymal stem cells, Molecular Medicine Reports, 2014,

    CrossRef

  24. 24
    George Ioannidis, Shelley Pallan, Alexandra Papaioannou, Manisha Mulgund, Lorena Rios, Jinhui Ma, Lehana Thabane, Kenneth S. Davison, Robert G. Josse, Christopher S. Kovacs, Nancy Kreiger, Wojciech P. Olszynski, Jerilynn C. Prior, Tanveer Towheed, Jonathan D. Adachi, Glucocorticoids predict 10-year fragility fracture risk in a population-based ambulatory cohort of men and women: Canadian Multicentre Osteoporosis Study (CaMos), Archives of Osteoporosis, 2014, 9, 1

    CrossRef

  25. 25
    Rebecca J. Moon, Nicholas C. Harvey, Identification of patient profile for treatment, Best Practice & Research Clinical Endocrinology & Metabolism, 2014, 28, 6, 767

    CrossRef

  26. 26
    C. Klop, F. de Vries, T. Vinks, M. J. Kooij, T. P. van Staa, J. W. J. Bijlsma, A. C. G. Egberts, M. L. Bouvy, Increase in prophylaxis of glucocorticoid-induced osteoporosis by pharmacist feedback: a randomised controlled trial, Osteoporosis International, 2014, 25, 1, 385

    CrossRef

  27. 27
    Antonio Naranjo, Rubén López, Blanca García-Magallón, Laura Cáceres, Félix Francisco, Mercedes Jiménez-Palop, Soledad Ojeda-Bruno, Longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica, Rheumatology International, 2014, 34, 10, 1459

    CrossRef

  28. 28
    Kazunori Inoue, Takayuki Hamano, Nobuhito Nango, Isao Matsui, Kodo Tomida, Satoshi Mikami, Naohiko Fujii, Chikako Nakano, Yoshitsugu Obi, Akihiro Shimomura, Yasuo Kusunoki, Hiromi Rakugi, Yoshitaka Isaka, Yoshiharu Tsubakihara, Multidetector-row computed tomography is useful to evaluate the therapeutic effects of bisphosphonates in glucocorticoid-induced osteoporosis, Journal of Bone and Mineral Metabolism, 2014, 32, 3, 271

    CrossRef

  29. 29
    A. C. Looker, Relationship between femur neck bone mineral density and prevalent chronic obstructive pulmonary disease (COPD) or COPD mortality in older non-Hispanic white adults from NHANES III, Osteoporosis International, 2014, 25, 3, 1043

    CrossRef

  30. 30
    Laura E. Targownik, Charles N. Bernstein, William D. Leslie, Risk factors and management of osteoporosis in inflammatory bowel disease, Current Opinion in Gastroenterology, 2014, 30, 2, 168

    CrossRef

  31. 31
    Tânia Santiago, José António P. Silva, Safety of low- to medium-dose glucocorticoid treatment in rheumatoid arthritis: myths and reality over the years, Annals of the New York Academy of Sciences, 2014, 1318, 1
  32. 32
    Bhadran Bose, Earl D. Silverman, Joanne M. Bargman, Ten Common Mistakes in the Management of Lupus Nephritis, American Journal of Kidney Diseases, 2014, 63, 4, 667

    CrossRef

  33. 33
    Barbara C Silva, William D Leslie, Heinrich Resch, Olivier Lamy, Olga Lesnyak, Neil Binkley, Eugene V McCloskey, John A Kanis, John P Bilezikian, Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image, Journal of Bone and Mineral Research, 2014, 29, 3
  34. 34
    Robert A. Overman, Joshua C. Toliver, Jun-Yen Yeh, Margaret L. Gourlay, Chad L. Deal, United States Adults Meeting 2010 American College of Rheumatology Criteria for Treatment and Prevention of Glucocorticoid-Induced Osteoporosis, Arthritis Care & Research, 2014, 66, 11
  35. 35
    Fabio M. Ulivieri, Barbara C. Silva, Francesco Sardanelli, Didier Hans, John P. Bilezikian, Renata Caudarella, Utility of the trabecular bone score (TBS) in secondary osteoporosis, Endocrine, 2014, 47, 2, 435

    CrossRef

  36. 36
    Randy M. Leung, Keith Dinnie, Timothy L. Smith, When do the risks of repeated courses of corticosteroids exceed the risks of surgery?, International Forum of Allergy & Rhinology, 2014, 4, 11
  37. 37
    Dora Liu, Alexandra Ahmet, Leanne Ward, Preetha Krishnamoorthy, Efrem D Mandelcorn, Richard Leigh, Jacques P Brown, Albert Cohen, Harold Kim, A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy, Allergy, Asthma & Clinical Immunology, 2013, 9, 1, 30

    CrossRef

  38. 38
    Martha C. Castaño-Betancourt, Fernando Rivadeneira, Sita Bierma-Zeinstra, Hanneke J. M. Kerkhof, Albert Hofman, Andre G. Uitterlinden, Joyce B. J. van Meurs, Bone parameters across different types of hip osteoarthritis and their relationship to osteoporotic fracture risk, Arthritis & Rheumatism, 2013, 65, 3
  39. 39
    Claus-C Glüer, Fernando Marin, Johann D Ringe, Federico Hawkins, Rüdiger Möricke, Nikolaos Papaioannu, Parvis Farahmand, Salvatore Minisola, Guillermo Martínez, Joan M Nolla, Christopher Niedhart, Nuria Guañabens, Ranuccio Nuti, Emilio Martín-Mola, Friederike Thomasius, Georgios Kapetanos, Jaime Peña, Christian Graeff, Helmut Petto, Beatriz Sanz, Andreas Reisinger, Philippe K Zysset, Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial, Journal of Bone and Mineral Research, 2013, 28, 6
  40. 40
    M. Pineton de Chambrun, B. Wechsler, D. Saadoun, Corticoterapia, EMC - Tratado de Medicina, 2013, 17, 3, 1

    CrossRef

  41. 41
    J. A. Kanis, E. V. McCloskey, H. Johansson, C. Cooper, R. Rizzoli, J.-Y. Reginster, European guidance for the diagnosis and management of osteoporosis in postmenopausal women, Osteoporosis International, 2013, 24, 1, 23

    CrossRef

  42. 42
    Irene EM Bultink, Marijke Baden, Willem F Lems, Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions, Expert Opinion on Pharmacotherapy, 2013, 14, 2, 185

    CrossRef

  43. 43
    Bjoern Buehring, Ravi Viswanathan, Neil Binkley, William Busse, Glucocorticoid-induced osteoporosis: An update on effects and management, Journal of Allergy and Clinical Immunology, 2013, 132, 5, 1019

    CrossRef

  44. 44
    Markus J Seibel, Mark S Cooper, Hong Zhou, Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives, The Lancet Diabetes & Endocrinology, 2013, 1, 1, 59

    CrossRef

  45. 45
    Béatrice Bouvard, Yves Gallois, Erick Legrand, Maurice Audran, Daniel Chappard, Glucocorticoids reduce alveolar and trabecular bone in mice, Joint Bone Spine, 2013, 80, 1, 77

    CrossRef

  46. 46
    S. R. Majumdar, S. N. Morin, L. M. Lix, W. D. Leslie, Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study, Osteoporosis International, 2013, 24, 9, 2493

    CrossRef

  47. 47
    Lora Giangregorio, Deena Lala, Kayla Hummel, Christopher Gordon, B. Catharine Craven, Measuring Apparent Trabecular Density and Bone Structure Using Peripheral Quantitative Computed Tomography at the Tibia: Precision in Participants With and Without Spinal Cord Injury, Journal of Clinical Densitometry, 2013, 16, 2, 139

    CrossRef

  48. 48
    Michael J Leach, Nicole L Pratt, Elizabeth E Roughead, Medicine Use among Older Australians Before and After Hip Fracture, Journal of Pharmacy Practice and Research, 2013, 43, 4
  49. 49
    Suhong Ye, Rendi Wu, Jie Wu, Multiple sclerosis and fracture, International Journal of Neuroscience, 2013, 123, 9, 609

    CrossRef

  50. 50
    K. Briot, C. Roux, Ostéoporose cortico-induite, La Revue de Médecine Interne, 2013, 34, 5, 315

    CrossRef

  51. 51
    Elisabeth APM Romme, Frank WJM Smeenk, Erica PA Rutten, Emiel FM Wouters, Osteoporosis in chronic obstructive pulmonary disease, Expert Review of Respiratory Medicine, 2013, 7, 4, 397

    CrossRef

  52. 52
    Robert A. Overman, Jun-Yen Yeh, Chad L. Deal, Prevalence of oral glucocorticoid usage in the United States: A general population perspective, Arthritis Care & Research, 2013, 65, 2
  53. 53
    Lauren Dudley, Lin Brown, Prevention of Glucocorticoid-Induced Fractures: Which Patients Should We Treat? Comment on the Article by Grossman et al, Arthritis Care & Research, 2013, 65, 9
  54. 54
    Z. E. Belaya, L. Y. Rozhinskaya, G. A. Melnichenko, A. G. Solodovnikov, N. V. Dragunova, A. V. Iljin, L. K. Dzeranova, I. I. Dedov, Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing’s syndrome, Osteoporosis International, 2013, 24, 8, 2191

    CrossRef

  55. 55
    Kent Søe, Ditte Marie Horslev Merrild, Jean-Marie Delaissé, Steering the osteoclast through the demineralization–collagenolysis balance, Bone, 2013, 56, 1, 191

    CrossRef

  56. 56
    Amanda L. Lorbergs, Norma J. MacIntyre, The International Classification of Functioning, Disability and Health (ICF) Core Sets: Application to a postmenopausal woman with rheumatoid arthritis and osteoporosis of the spine, Physiotherapy Theory and Practice, 2013, 29, 7, 547

    CrossRef

  57. 57
    Robert A. Adler, Robert S. Weinstein, Kenneth G. Saag, Osteoporosis, 2013,

    CrossRef

  58. 58
    John A. Kanis, Anders Odén, Helena Johansson, Eugene V. McCloskey, Osteoporosis, 2013,

    CrossRef

  59. 59
    Philip J. Saylor, Matthew R. Smith, Osteoporosis, 2013,

    CrossRef

  60. 60
    Sydney Lou Bonnick, Paul Miller, Osteoporosis, 2013,

    CrossRef

  61. 61
    S. Lekamwasam, J. D. Adachi, D. Agnusdei, J. Bilezikian, S. Boonen, F. Borgström, C. Cooper, A. Diez Perez, R. Eastell, L. C. Hofbauer, J. A. Kanis, B. L. Langdahl, O. Lesnyak, R. Lorenc, E. McCloskey, O. D. Messina, N. Napoli, B. Obermayer-Pietsch, S. H. Ralston, P. N. Sambrook, S. Silverman, M. Sosa, J. Stepan, G. Suppan, D. A. Wahl, J. E. Compston, A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis, Osteoporosis International, 2012, 23, 9, 2257

    CrossRef

  62. 62
    Arjuna Imbuldeniya, Natasha Jiwa, John Murphy, Bilateral atypical insufficiency fractures of the proximal tibia and a unilateral distal femoral fracture associated with long-term intravenous bisphosphonate therapy: a case report, Journal of Medical Case Reports, 2012, 6, 1, 50

    CrossRef

  63. 63
    Matti S. Aapro, Robert E. Coleman, Bone health management in patients with breast cancer: Current standards and emerging strategies, The Breast, 2012, 21, 1, 8

    CrossRef

  64. 64
    Bart L. Clarke, Corticosteroid-Induced Osteoporosis, American Journal of Clinical Dermatology, 2012, 13, 3, 167

    CrossRef

  65. 65
    E. M. Clark, V. C. Gould, L. Morrison, T. Masud, J. Tobias, Determinants of fracture risk in a UK-population-based cohort of older women: a cross-sectional analysis of the Cohort for Skeletal Health in Bristol and Avon (COSHIBA), Age and Ageing, 2012, 41, 1, 46

    CrossRef

  66. 66
    Hyun Jung Hwang, Si Young Park, Soon Hyuck Lee, Seung Bum Han, Kyung Han Ro, Differences in Bone Mineral Density between the Right and Left Hips in Postmenopausal Women, Journal of Korean Medical Science, 2012, 27, 6, 686

    CrossRef

  67. 67
    Alexander K. Meininger, Jason L. Koh, Evaluation of the Injured Runner, Clinics in Sports Medicine, 2012, 31, 2, 203

    CrossRef

  68. 68
    Eugene McCloskey, Helena Johansson, Anders Oden, John A. Kanis, Fracture risk assessment, Clinical Biochemistry, 2012, 45, 12, 887

    CrossRef

  69. 69
    L Joseph Melton, Lynn C Hartmann, Sara J Achenbach, Elizabeth J Atkinson, Terry M Therneau, Sundeep Khosla, Fracture risk in women with breast cancer: A population-based study, Journal of Bone and Mineral Research, 2012, 27, 5
  70. 70
    Eugene McCloskey, John A. Kanis, FRAX updates 2012, Current Opinion in Rheumatology, 2012, 24, 5, 554

    CrossRef

  71. 71
    C. M. Couris, R. D. Chapurlat, J. A. Kanis, H. Johansson, N. Burlet, P. D. Delmas, A. M. Schott, FRAX® probabilities and risk of major osteoporotic fracture in France, Osteoporosis International, 2012, 23, 9, 2321

    CrossRef

  72. 72
    Rafael Azagra, Genís Roca, Gloria Encabo, Amada Aguyé, Marta Zwart, Sílvia Güell, Núria Puchol, Emili Gene, Enrique Casado, Pilar Sancho, Silvia Solà, Pere Torán, Milagros Iglesias, Maria Gisbert, Francesc López-Expósito, Jesús Pujol-Salud, Yolanda Fernandez-Hermida, Ana Puente, Mireia Rosàs, Vicente Bou, Juan Antón, Gustavo Lansdberg, Juan Martín-Sánchez, Adolf Díez-Pérez, Daniel Prieto-Alhambra, FRAX® tool, the WHO algorithm to predict osteoporotic fractures: the first analysis of its discriminative and predictive ability in the Spanish FRIDEX cohort, BMC Musculoskeletal Disorders, 2012, 13, 1, 204

    CrossRef

  73. 73
    Uwe Gröber, Klaus Kisters, Influence of drugs on vitamin D and calcium metabolism, Dermato-Endocrinology, 2012, 4, 2, 158

    CrossRef

  74. 74
    Kieron B. L. Lim, Thomas D. Schiano, Long-Term Outcome After Liver Transplantation, Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2012, 79, 2
  75. 75
    R. Rizzoli, J. D. Adachi, C. Cooper, W. Dere, J. P. Devogelaer, A. Diez-Perez, J. A. Kanis, A. Laslop, B. Mitlak, S. Papapoulos, S. Ralston, S. Reiter, G. Werhya, J. Y. Reginster, Management of Glucocorticoid-Induced Osteoporosis, Calcified Tissue International, 2012, 91, 4, 225

    CrossRef

  76. 76
    Masahiko Takahata, Jason R. Maher, Subhash C. Juneja, Jason Inzana, Lianping Xing, Edward M. Schwarz, Andrew J. Berger, Hani A. Awad, Mechanisms of bone fragility in a mouse model of glucocorticoid-treated rheumatoid arthritis: Implications for insufficiency fracture risk, Arthritis & Rheumatism, 2012, 64, 11
  77. 77
    Karen Walker-Bone, Recognizing and treating secondary osteoporosis, Nature Reviews Rheumatology, 2012, 8, 8, 480

    CrossRef

  78. 78
    Ana Maria Rodrigues, Joana Caetano-Lopes, Ana Catarina Vale, Inês Aleixo, Ana Sofia Pena, Alexandra Faustino, Alexandre Sepriano, Joaquim Polido-Pereira, Elsa Vieira-Sousa, Raquel Lucas, José Carlos Romeu, Jacinto Monteiro, Maria Fátima Vaz, João Eurico Fonseca, Helena Canhão, Smoking is a predictor of worse trabecular mechanical performance in hip fragility fracture patients, Journal of Bone and Mineral Metabolism, 2012, 30, 6, 692

    CrossRef

  79. 79
    Ewa Sewerynek, Michal Stuss, Steroid-induced osteoporosis, Aging Health, 2012, 8, 5, 471

    CrossRef

  80. 80
    Toshitaka Nakamura, Mitsuharu Osawa, Makoto Itoh, Hiromichi Yamaguchi, Norio Iinuma, Yutaka Hayakawa, Hitoshi Suzuki, Toshiaki Kamisaki, Satoshi Iwayama, Masahiko Nishikawa, The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study, Journal of Bone and Mineral Metabolism, 2012, 30, 6, 715

    CrossRef

  81. 81
    Debby den Uyl, Irene E. M. Bultink, Willem F. Lems, Advances in Glucocorticoid-Induced Osteoporosis, Current Rheumatology Reports, 2011, 13, 3, 233

    CrossRef

  82. 82
    Takao Sugiyama, Sawako Suzuki, Tomohiko Yoshida, Takafumi Mayama, Naoko Hashimoto, Keiko Suyama, Tomoaki Tanaka, Makoto Sueishi, Ichiro Tatsuno, Age, Initial Dose and Dose Increase are Independent Risk Factors for Symptomatic Vertebral Fractures in Glucocorticoid-Treated Male Patients, Internal Medicine, 2011, 50, 8, 817

    CrossRef

  83. 83
    K. de Groot, E. Märker-Hermann, Behandlung der Komorbiditäten entzündlich-rheumatischer Erkrankungen, Der Internist, 2011, 52, 6, 688

    CrossRef

  84. 84
    Kerry Siminoski, Margaret O'Keeffe, Jacques Lévesque, David Hanley, Jacques P. Brown, Canadian Association of Radiologists Technical Standards for Bone Mineral Densitometry Reporting, Canadian Association of Radiologists Journal, 2011, 62, 3, 166

    CrossRef

  85. 85
    A. J. Taylor, L. C. Gary, T. Arora, D. J. Becker, J. R. Curtis, M. L. Kilgore, M. A. Morrisey, K. G. Saag, R. Matthews, H. Yun, W. Smith, E. Delzell, Clinical and demographic factors associated with fractures among older Americans, Osteoporosis International, 2011, 22, 4, 1263

    CrossRef

  86. You have free access to this content86
    Juliet Compston, Clinical Question: What is the best approach to managing glucocorticoid-induced osteoporosis?, Clinical Endocrinology, 2011, 74, 5
  87. 87
    N. M. Cummins, E. K. Poku, M. R. Towler, O. M. O’Driscoll, S. H. Ralston, Clinical Risk Factors for Osteoporosis in Ireland and the UK: A Comparison of FRAX and QFractureScores, Calcified Tissue International, 2011, 89, 2, 172

    CrossRef

  88. 88
    W. D. Leslie, C. Berger, L. Langsetmo, L. M. Lix, J. D. Adachi, D. A. Hanley, G. Ioannidis, R. G. Josse, C. S. Kovacs, T. Towheed, S. Kaiser, W. P. Olszynski, J. C. Prior, S. Jamal, N. Kreiger, D. Goltzman, Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts, Osteoporosis International, 2011, 22, 6, 1873

    CrossRef

  89. 89
    Enrique Casado, Jorge Malouf, Manuel M. Caamaño, Esteban Salas, Juan M. Sánchez-Bursón, María L. Rentero, Gabriel Herrero-Beaumont, Defining High Risk of Osteoporotic Fracture, Journal of Clinical Rheumatology, 2011, 17, Suppl 3, S59

    CrossRef

  90. 90
    L.-A. Fraser, L. Langsetmo, C. Berger, G. Ioannidis, D. Goltzman, J. D. Adachi, A. Papaioannou, R. Josse, C. S. Kovacs, W. P. Olszynski, T. Towheed, D. A. Hanley, S. M. Kaiser, J. Prior, S. Jamal, N. Kreiger, J. P. Brown, H. Johansson, A. Oden, E. McCloskey, J. A. Kanis, W. D. Leslie, Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos, Osteoporosis International, 2011, 22, 3, 829

    CrossRef

  91. 91
    L Joseph Melton, Michael M Lieber, Elizabeth J Atkinson, Sara J Achenbach, Horst Zincke, Terry M Therneau, Sundeep Khosla, Fracture risk in men with prostate cancer: A population-based study, Journal of Bone and Mineral Research, 2011, 26, 8
  92. 92
    Gauthier Morel, Emmanuel Biver, Séverine Borg, Florence Chopin, Emmanuel Hoppé, Gérald Rajzbaum, Glucocorticoid-induced osteoporosis: when and who should we treat?, Joint Bone Spine, 2011, 78, S214

    CrossRef

  93. 93
    J. A. Kanis, H. Johansson, A. Oden, E. V. McCloskey, Guidance for the adjustment of FRAX according to the dose of glucocorticoids, Osteoporosis International, 2011, 22, 3, 809

    CrossRef

  94. 94
    J. A. Kanis, D. Hans, C. Cooper, S. Baim, J. P. Bilezikian, N. Binkley, J. A. Cauley, J. E. Compston, B. Dawson-Hughes, G. El-Hajj Fuleihan, H. Johansson, W. D. Leslie, E. M. Lewiecki, M. Luckey, A. Oden, S. E. Papapoulos, C. Poiana, R. Rizzoli, D. A. Wahl, E. V. McCloskey, Interpretation and use of FRAX in clinical practice, Osteoporosis International, 2011, 22, 9, 2395

    CrossRef

  95. 95
    Wenbin Liang, Tanya Chikritzhs, Andy H. Lee, Is Asthma Associated with Increased Risk of Injury?, Journal of Asthma, 2011, 48, 3, 311

    CrossRef

  96. 96
    Rahul Dubey, Jeanie Chui, John Langford-Smith, Helen Danesh-Meyer, Ian C. Francis, Jaw Dropping: The Necessity of a History and a Biopsy in Suspected Temporal Arteritis, Neuro-Ophthalmology, 2011, 35, 3, 156

    CrossRef

  97. 97
    Christian Roux, Gérald Rajzbaum, Gauthier Morel, Erick Legrand, Michel Laroche, Emmanuel Hoppé, Florence Chopin, Séverine Borg, Emmanuel Biver, Bernard Cortet, Thierry Thomas, Management of glucocorticoid-induced osteoporosis: Lessons for clinical practice, Joint Bone Spine, 2011, 78, S222

    CrossRef

  98. 98
    Managing osteoporosis in primary care: Highlights from Osteoporosis Canada guidelines, Canadian Pharmacists Journal, 2011, 144, sp1, S5

    CrossRef

  99. 99
    Kaichi KANEKO, Shinichi KAWAI, Mechanisms and therapeutics of glucocorticoid-induced osteoporosis., Japanese Journal of Clinical Immunology, 2011, 34, 3, 138

    CrossRef

  100. 100
    Gillian Tufts, New Treatment Approach for Osteopenia, Journal of Midwifery & Women’s Health, 2011, 56, 1
  101. 101
    Edward S. Leib, Kenneth G. Saag, Jonathan D. Adachi, Piet P. Geusens, Neil Binkley, Eugene V. McCloskey, Didier B. Hans, Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture, Journal of Clinical Densitometry, 2011, 14, 3, 212

    CrossRef

  102. 102
    U. Lange, U. Müller-Ladner, J. Pfeilschifter, Osteoporose, Der Internist, 2011, 52, 7, 843

    CrossRef

  103. 103
    C. Marcelli, Ostéoporose cortisonique, EMC - Appareil locomoteur, 2011, 6, 3, 1

    CrossRef

  104. 104
    Béatrice Bouvard, Erick Legrand, Maurice Audran, Daniel Chappard, Ostéoporose secondaire à la corticothérapie systémique, Revue du Rhumatisme Monographies, 2011, 78, 2, 69

    CrossRef

  105. 105
    Brian Lentle, Angela M. Cheung, David A. Hanley, William D. Leslie, David Lyons, Alexandra Papaioannou, Stephanie Atkinson, Jacques P. Brown, Sidney Feldman, Anthony B. Hodsman, Abida Sophina Jamal, Robert G. Josse, Stephanie M. Kaiser, Brent Kvern, Suzanne Morin, Kerry Siminoski, Osteoporosis Canada 2010 Guidelines for the Assessment of Fracture Risk, Canadian Association of Radiologists Journal, 2011, 62, 4, 243

    CrossRef

  106. 106
    C. Marcelli, Osteoporosis inducida por corticoides, EMC - Aparato Locomotor, 2011, 44, 4, 1

    CrossRef

  107. 107
    K. H. Rubin, B. Abrahamsen, A. P. Hermann, M. Bech, J. Gram, K. Brixen, Prevalence of risk factors for fractures and use of DXA scanning in Danish women. A regional population-based study, Osteoporosis International, 2011, 22, 5, 1401

    CrossRef

  108. 108
    Muhammad Haroon, Milo Ó Rathaille, Donncha Ó Gradaigh, Prevention of glucocorticoid-induced osteoporosis: a re-audit of dual-energy x-ray absorptiometry scan access and management guideline compliance, International Journal of Clinical Rheumatology, 2011, 6, 2, 251

    CrossRef

  109. 109
    Mikko T. Ovaska, Tatu J. Mäkinen, Rami Madanat, Simultaneous bilateral subtrochanteric fractures following risedronate therapy, Journal of Orthopaedic Science, 2011, 16, 4, 467

    CrossRef

  110. 110
    Marloes T Bazelier, Tjeerd van Staa, Bernard MJ Uitdehaag, Cyrus Cooper, Hubert GM Leufkens, Peter Vestergaard, Joan Bentzen, Frank de Vries, The risk of fracture in patients with multiple sclerosis: The UK general practice research, Journal of Bone and Mineral Research, 2011, 26, 9
  111. 111
    Michael Maricic, Update on Glucocorticoid-Induced Osteoporosis, Rheumatic Disease Clinics of North America, 2011, 37, 3, 415

    CrossRef

  112. 112
    Sydney Bonnick, Rheumatology, 2011,

    CrossRef

  113. 113
    Kenneth G. Saag, Rheumatology, 2011,

    CrossRef

  114. 114
    Wim Janssens, Chantal Mathieu, Steven Boonen, Marc Decramer, Vitamins and the Immune System, 2011,

    CrossRef

  115. 115
    Martin Root, John Anderson, Diet, Nutrients, and Bone Health, 2011,

    CrossRef

  116. 116
    David Ontjes, Diet, Nutrients, and Bone Health, 2011,

    CrossRef

  117. 117
    Carmen Gómez Vaquero, Daniel Roig Vilaseca, ¿Qué es el FRAX?: pros y contras, Seminarios de la Fundación Española de Reumatología, 2010, 11, 3, 100

    CrossRef

  118. 118
    J. S. B. Carvas, R. M. R. Pereira, V. F. Caparbo, P. Fuller, C. A. Silveira, L. A. P. Lima, E. Bonfa, S. B. V. Mello, A single dose of zoledronic acid reverses the deleterious effects of glucocorticoids on titanium implant osseointegration, Osteoporosis International, 2010, 21, 10, 1723

    CrossRef

  119. 119
    Jennifer M. Grossman, Rebecca Gordon, Veena K. Ranganath, Chad Deal, Liron Caplan, Weiling Chen, Jeffrey R. Curtis, Daniel E. Furst, Maureen McMahon, Nivedita M. Patkar, Elizabeth Volkmann, Kenneth G. Saag, American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis, Arthritis Care & Research, 2010, 62, 11
  120. 120
    Glen M. Blake, Ignac Fogelman, An Update on Dual-Energy X-Ray Absorptiometry, Seminars in Nuclear Medicine, 2010, 40, 1, 62

    CrossRef

  121. 121
    Philip J. Saylor, Donald S. Kaufman, M. Dror Michaelson, Richard J. Lee, Matthew R. Smith, Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer, The Journal of Urology, 2010, 183, 6, 2200

    CrossRef

  122. 122
    L. C. Hofbauer, C. Hamann, P. R. Ebeling, Approach to the patient with secondary osteoporosis, European Journal of Endocrinology, 2010, 162, 6, 1009

    CrossRef

  123. 123
    Joop P. W. van den Bergh, Tineke A. C. M. van Geel, Willem F. Lems, Piet P. Geusens, Assessment of Individual Fracture Risk: FRAX and Beyond, Current Osteoporosis Reports, 2010, 8, 3, 131

    CrossRef

  124. 124
    Harri Sievänen, Bone densitometry and true BMD accuracy for predicting fractures: what are the alternatives?, International Journal of Clinical Rheumatology, 2010, 5, 3, 371

    CrossRef

  125. 125
    P J Saylor, M R Smith, Bone health and prostate cancer, Prostate Cancer and Prostatic Diseases, 2010, 13, 1, 20

    CrossRef

  126. 126
    A. Lehouck, H. van Remoortel, T. Troosters, M. Decramer, W. Janssens, BPCO et métabolisme osseux: une mise à jour clinique, Revue des Maladies Respiratoires, 2010, 27, 10, 1231

    CrossRef

  127. 127
    Seung Hun Lee, Young-Ho Khang, Kyeong-Hye Lim, Beom-Jun Kim, Jung-Min Koh, Ghi Su Kim, Hyungrae Kim, Nam H Cho, Clinical risk factors for osteoporotic fracture: A population-based prospective cohort study in Korea, Journal of Bone and Mineral Research, 2010, 25, 2
  128. 128
    T. Beukelman, K. G. Saag, J. R. Curtis, M. L. Kilgore, M. Pisu, Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis, Osteoporosis International, 2010, 21, 9, 1573

    CrossRef

  129. 129
    J. A. Kanis, E. V. McCloskey, H. Johansson, A. Oden, O. Ström, F. Borgström, Development and use of FRAX® in osteoporosis, Osteoporosis International, 2010, 21, S2, 407

    CrossRef

  130. 130
    E. Kingwell, J. C. Prior, P. A. Ratner, S. M. Kennedy, Direct-to-participant feedback and awareness of bone mineral density testing results in a population-based sample of mid-aged Canadians, Osteoporosis International, 2010, 21, 2, 307

    CrossRef

  131. 131
    Masaki Takahashi, Kentarou Ushijima, Yohei Hayashi, Tomohiro Maekawa, Hitoshi Ando, Shu-ichi Tsuruoka, Akio Fujimura, Dosing-time dependent effect of dexamethasone on bone density in rats, Life Sciences, 2010, 86, 1-2, 24

    CrossRef

  132. 132
    H. Kaji, Y. Kuroki, Y. Murakawa, I. Funakawa, Y. Funasaka, F. Kanda, T. Sugimoto, Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study, Osteoporosis International, 2010, 21, 9, 1565

    CrossRef

  133. 133
    B.L. Clarke, Effects of Teriparatide Versus Alendronate for Treating Glucocorticoid-Induced Osteoporosis: Thirty-Six–Month Results of a Randomized, Double-Blind, Controlled Trial, Yearbook of Endocrinology, 2010, 2010, 223

    CrossRef

  134. 134
    F. Hawkins Carranza, G. Martínez Díaz-Guerra, S. Guadalix Iglesias, R. Sánchez Windt, M. Calatayud Gutiérrez, Factores de riesgo de osteoporosis y fracturas. Quiénes deben de ser estudiados. Estimación de probabilidad del riesgo de fracturas, Medicine - Programa de Formación Médica Continuada Acreditado, 2010, 10, 60, 4128

    CrossRef

  135. 135
    E. Michael Lewiecki, Fracture Risk Assessment in Clinical Practice: T-scores, FRAX, and Beyond, Clinical Reviews in Bone and Mineral Metabolism, 2010, 8, 3, 101

    CrossRef

  136. 136
    K. Lippuner, H. Johansson, J. A. Kanis, R. Rizzoli, FRAX® assessment of osteoporotic fracture probability in Switzerland, Osteoporosis International, 2010, 21, 3, 381

    CrossRef

  137. 137
    Béatrice Bouvard, Erick Legrand, Maurice Audran, Daniel Chappard, Glucocorticoid-Induced Osteoporosis: A Review, Clinical Reviews in Bone and Mineral Metabolism, 2010, 8, 1, 15

    CrossRef

  138. 138
    Kent Søe, Jean-Marie Delaissé, Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle, Journal of Bone and Mineral Research, 2010, 25, 10
  139. 139
    T. Willenberg, N. Diehm, M. Zwahlen, C. Kalka, D.-D. Do, S. Gretener, J. Ortmann, I. Baumgartner, Impact of Long-term Corticosteroid Therapy on the Distribution Pattern of Lower Limb Atherosclerosis, European Journal of Vascular and Endovascular Surgery, 2010, 39, 4, 441

    CrossRef

  140. 140
    Takao Sugiyama, Sawako Suzuki, Tomohiko Yoshida, Keiko Suyama, Tomoaki Tanaka, Makoto Sueishi, Ichiro Tatsuno, Incidence of symptomatic vertebral fractures in women of childbearing age newly treated with high-dose glucocorticoid, Gender Medicine, 2010, 7, 3, 218

    CrossRef

  141. 141
    William D Leslie, Lisa M Lix, Helena Johansson, Anders Oden, Eugene McCloskey, John A Kanis, Independent clinical validation of a Canadian FRAX tool: Fracture prediction and model calibration, Journal of Bone and Mineral Research, 2010, 25, 11
  142. 142
    Kyu-Hyun Yang, Si-Young Park, Sang-Won Park, Soon-Hyuck Lee, Seung-Beom Han, Woong-Kyo Jung, Suk-Jin Kim, Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate, Journal of Bone and Mineral Metabolism, 2010, 28, 6, 713

    CrossRef

  143. 143
    J. Braun, J. Pfeilschifter, Leitliniengerechte Diagnostik und Therapie der Osteoporose 2010, Zeitschrift für Rheumatologie, 2010, 69, 4, 327

    CrossRef

  144. 144
    Juliet Compston, Management of glucocorticoid-induced osteoporosis, Nature Reviews Rheumatology, 2010, 6, 2, 82

    CrossRef

  145. 145
    Ethel S. Siris, Sanford Baim, Aurelia Nattiv, Primary Care Use of FRAX®: Absolute Fracture Risk Assessment in Postmenopausal Women and Older Men, Postgraduate Medicine, 2010, 122, 1, 82

    CrossRef

  146. 146
    William D. Leslie, Lisa M. Lix, Simplified 10-Year Absolute Fracture Risk Assessment: A Comparison of Men and Women, Journal of Clinical Densitometry, 2010, 13, 2, 141

    CrossRef

  147. 147
    H. Kaji, M. Yamauchi, T. Yamaguchi, T. Sugimoto, Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid, Osteoporosis International, 2010, 21, 9, 1585

    CrossRef

  148. 148
    John T. Schousboe, Osteoporosis in Men, 2010,

    CrossRef

  149. 149
    Tuan V Nguyen, John A Eisman, Osteoporosis in Men, 2010,

    CrossRef

  150. 150
    E. Michael Lewiecki, Sanford Baim, John P. Bilezikian, Richard Eastell, Meryl S. LeBoff, Paul D. Miller, 2008 Santa Fe Bone Symposium: Update on Osteoporosis, Journal of Clinical Densitometry, 2009, 12, 2, 135

    CrossRef

  151. 151
    Peyman Hadji, Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis, Critical Reviews in Oncology/Hematology, 2009, 69, 1, 73

    CrossRef

  152. 152
    Nigel J Bundred, Aromatase inhibitors and bone health, Current Opinion in Obstetrics and Gynecology, 2009, 21, 1, 60

    CrossRef

  153. 153
    John A. Kanis, Helena. Johansson, Anders Oden, Eugene V. McCloskey, Assessment of fracture risk, European Journal of Radiology, 2009, 71, 3, 392

    CrossRef

  154. 154
    H. Johansson, J. A. Kanis, A. Oden, O. Johnell, E. McCloskey, BMD, clinical risk factors and their combination for hip fracture prevention, Osteoporosis International, 2009, 20, 10, 1675

    CrossRef

  155. 155
    K. Hayashi, M. Yamamoto, Y. Murakawa, M. Yamauchi, H. Kaji, T. Yamaguchi, T. Sugimoto, Bone fragility in male glucocorticoid-induced osteoporosis is not defined by bone mineral density, Osteoporosis International, 2009, 20, 11, 1889

    CrossRef

  156. 156
    Tobias Johannes de Villiers, Bone health and osteoporosis in postmenopausal women, Best Practice & Research Clinical Obstetrics & Gynaecology, 2009, 23, 1, 73

    CrossRef

  157. 157
    Peter Vestergaard, Bone metabolism in type 2 diabetes and role of thiazolidinediones, Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 2, 125

    CrossRef

  158. 158
    Antonio Bazarra-Fernández, Cálculo de la resistencia ósea en la menopausia, Progresos de Obstetricia y Ginecología, 2009, 52, 12, 722

    CrossRef

  159. 159
    C. B. Franco, G. Paz-Filho, P. E. Gomes, V. B. Nascimento, C. A. M. Kulak, C. L. Boguszewski, V. Z. C. Borba, Chronic obstructive pulmonary disease is associated with osteoporosis and low levels of vitamin D, Osteoporosis International, 2009, 20, 11, 1881

    CrossRef

  160. 160
    Kenneth G. Saag, Jose R. Zanchetta, Jean-Pierre Devogelaer, Robert A. Adler, Richard Eastell, Kyoungah See, John H. Krege, Kelly Krohn, Margaret R. Warner, Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six–month results of a randomized, double-blind, controlled trial, Arthritis & Rheumatism, 2009, 60, 11
  161. 161
    Bich N. H. Tran, Nguyen D. Nguyen, Jacqueline R. Center, John A. Eisman, Tuan V. Nguyen, Enhancement of Absolute Fracture Risk Prognosis with Genetic Marker: The Collagen I Alpha 1 Gene, Calcified Tissue International, 2009, 85, 5, 379

    CrossRef

  162. 162
    John A. Kanis, Anders Oden, Helena Johansson, Fredrik Borgström, Oskar Ström, Eugene McCloskey, FRAX® and its applications to clinical practice, Bone, 2009, 44, 5, 734

    CrossRef

  163. 163
    Eugene V. McCloskey, Helena Johansson, Anders Oden, John A. Kanis, From relative risk to absolute fracture risk calculation: The FRAX algorithm, Current Osteoporosis Reports, 2009, 7, 3, 77

    CrossRef

  164. 164
    Stuart L. Silverman, Nancy E. Lane, Glucocorticoid-induced osteoporosis, Current Osteoporosis Reports, 2009, 7, 1, 23

    CrossRef

  165. 165
    Takao SUGIYAMA, Ichiro TATSUNO, Sawako SUZUKI, Tomohiko YOSHIDA, Tomoaki TANAKA, Makoto SUEISHI, Yasushi SAITO, Incidence of Symptomatic Vertebral Fracture with Highdose Glucocorticoid Treatment in the Chiba-Shimoshizu Rheumatic Cohort between 1986 and 2006, Endocrine Journal, 2009, 56, 4, 591

    CrossRef

  166. 166
    Y Kozai, R Kawamata, T Sakurai, M Kanno, I Kashima, Influence of prednisolone-induced osteoporosis on bone mass and bone quality of the mandible in rats, Dentomaxillofacial Radiology, 2009, 38, 1, 34

    CrossRef

  167. 167
    Ken M Kunisaki, Edward N Janoff, Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses, The Lancet Infectious Diseases, 2009, 9, 8, 493

    CrossRef

  168. 168
    Mary Knudtson, Osteoporosis: Background and Overview, The Journal for Nurse Practitioners, 2009, 5, 6, S4

    CrossRef

  169. 169
    Frank Bonura, Prevention, Screening, and Management of Osteoporosis: An Overview of the Current Strategies, Postgraduate Medicine, 2009, 121, 4, 5

    CrossRef

  170. 170
    Philip J. Saylor, Nancy L. Keating, Matthew R. Smith, Prostate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapy, Journal of General Internal Medicine, 2009, 24, S2, 389

    CrossRef

  171. 171
    A. Papaioannou, C. C. Kennedy, A. Cranney, G. Hawker, J. P. Brown, S. M. Kaiser, W. D. Leslie, C. J. M. O’Brien, A. M. Sawka, A. Khan, K. Siminoski, G. Tarulli, D. Webster, J. McGowan, J. D. Adachi, Risk factors for low BMD in healthy men age 50 years or older: a systematic review, Osteoporosis International, 2009, 20, 4, 507

    CrossRef

  172. 172
    J. R. Curtis, T. Arora, M. Donaldson, G. S. Alarcón, L. F. Callahan, L. W. Moreland, S. L. Bridges, T. R. Mikuls, Skeletal health among African Americans with recent-onset rheumatoid arthritis, Arthritis Care & Research, 2009, 61, 10
  173. 173
    Larry W. Moreland, Jeffrey R. Curtis, Systemic Nonarticular Manifestations of Rheumatoid Arthritis: Focus on Inflammatory Mechanisms, Seminars in Arthritis and Rheumatism, 2009, 39, 2, 132

    CrossRef

  174. 174
    E. V. McCloskey, H. Johansson, A. Oden, S. Vasireddy, K. Kayan, K. Pande, T. Jalava, J. A. Kanis, Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study, Osteoporosis International, 2009, 20, 5, 811

    CrossRef

  175. 175
    S. W. Y. Tsang, A. W. C. Kung, J. A. Kanis, H. Johansson, A. Oden, Ten-year fracture probability in Hong Kong Southern Chinese according to age and BMD femoral neck T-scores, Osteoporosis International, 2009, 20, 11, 1939

    CrossRef

  176. 176
    B. L. Langdahl, F. Marin, E. Shane, H. Dobnig, J. R. Zanchetta, M. Maricic, K. Krohn, K. See, M. R. Warner, Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status, Osteoporosis International, 2009, 20, 12, 2095

    CrossRef

  177. 177
    Glen M. Blake, Ignac Fogelman, The clinical role of dual energy X-ray absorptiometry, European Journal of Radiology, 2009, 71, 3, 406

    CrossRef

  178. 178
    Karsten E. Dreinhöfer, Sabine Weilbach, Alterstraumatologie, 2009,

    CrossRef

  179. 179
    JB Richards, F Rivadeneira, M Inouye, TM Pastinen, N Soranzo, SG Wilson, T Andrew, M Falchi, R Gwilliam, KR Ahmadi, AM Valdes, P Arp, P Whittaker, DJ Verlaan, M Jhamai, V Kumanduri, M Moorhouse, JB van Meurs, A Hofman, HAP Pols, D Hart, G Zhai, BS Kato, BH Mullin, F Zhang, P Deloukas, AG Uitterlinden, TD Spector, Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study, The Lancet, 2008, 371, 9623, 1505

    CrossRef

  180. 180
    J. A. Kanis, E. V. McCloskey, H. Johansson, O. Strom, F. Borgstrom, A. Oden, Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK, Osteoporosis International, 2008, 19, 10, 1395

    CrossRef

  181. 181
    John T Schousboe, Cost Effectiveness of Screen-and-Treat Strategies for Low Bone Mineral Density, Applied Health Economics and Health Policy, 2008, 6, 1, 1

    CrossRef

  182. 182
    N. D. Nguyen, S. A. Frost, J. R. Center, J. A. Eisman, T. V. Nguyen, Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks, Osteoporosis International, 2008, 19, 10, 1431

    CrossRef

  183. 183
    H. DEVLIN, K. HORNER, Diagnosis of osteoporosis in oral health care, Journal of Oral Rehabilitation, 2008, 35, 2
  184. 184
    Christine Simonelli, Robert A. Adler, Glen M. Blake, JoAnn P. Caudill, Aliya Khan, Ed Leib, Michael Maricic, Jerilynn C. Prior, Sergio Ragi Eis, Cliff Rosen, David L. Kendler, Dual-Energy X-Ray Absorptiometry Technical Issues: The 2007 ISCD Official Positions, Journal of Clinical Densitometry, 2008, 11, 1, 109

    CrossRef

  185. 185
    Javier P. Gisbert, C. Santander, Josep M. Piqué, Fernando Gomollón, Esther Garcia Planella, Enfermedad inflamatoria intestinal, Gastroenterología y Hepatología, 2008, 31, 9, 618

    CrossRef

  186. 186
    J. A. Kanis, N. Burlet, C. Cooper, P. D. Delmas, J.-Y. Reginster, F. Borgstrom, R. Rizzoli, European guidance for the diagnosis and management of osteoporosis in postmenopausal women, Osteoporosis International, 2008, 19, 4, 399

    CrossRef

  187. 187
    L Joseph Melton, Cynthia L Leibson, Sara J Achenbach, Terry M Therneau, Sundeep Khosla, Fracture Risk in Type 2 Diabetes: Update of a Population-Based Study, Journal of Bone and Mineral Research, 2008, 23, 8
  188. 188
    JB Richards, F Rivadeneira, AG Uitterlinden, TD Spector, Fractures are not in genes – Authors' reply, The Lancet, 2008, 372, 9648, 1460

    CrossRef

  189. 189
    J. A. Kanis, O. Johnell, A. Oden, H. Johansson, E. McCloskey, FRAX™ and the assessment of fracture probability in men and women from the UK, Osteoporosis International, 2008, 19, 4, 385

    CrossRef

  190. 190
    John A Kanis, Anders Oden, Helena Johansson, Eugene McCloskey, FRAX™ and the assessment of fracture probability: An introduction, IBMS BoneKEy, 2008, 5, 3, 114

    CrossRef

  191. 191
    Hiroshi Kaji, Mika Yamauchi, Kazuo Chihara, Toshitsugu Sugimoto, Glucocorticoid Excess Affects Cortical Bone Geometry in Premenopausal, but not Postmenopausal, Women, Calcified Tissue International, 2008, 82, 3, 182

    CrossRef

  192. 192
    M. Sosa Henríquez, M. Díaz Curiel, A. Díez Pérez, C. Gómez Alonso, J. González Macías, J. Farrerons Minguella, J. Filgueira Rubio, L. Mellibovsky Saidler, X. Nogués Solán, D. Hernández Hernández, Guía de prevención y tratamiento de la osteoporosis inducida por glucocorticoides de la Sociedad Española de Medicina Interna, Revista Clínica Española, 2008, 208, 1, 33

    CrossRef

  193. 193
    B. Dawson-Hughes, A. N. A. Tosteson, L. J. Melton, S. Baim, M. J. Favus, S. Khosla, R. L. Lindsay, Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA, Osteoporosis International, 2008, 19, 4, 449

    CrossRef

  194. 194
    William C. Logan, Richard Sloane, Kenneth W. Lyles, Barry Goldstein, Helen M. Hoenig, Incidence of Fractures in a Cohort of Veterans With Chronic Multiple Sclerosis or Traumatic Spinal Cord Injury, Archives of Physical Medicine and Rehabilitation, 2008, 89, 2, 237

    CrossRef

  195. 195
    C. L. NOBLE, J. MCCULLOUGH, W. HO, C. W. LEES, E. NIMMO, H. DRUMMOND, S. BEAR, J. HANNAN, C. MILLAR, S. H. RALSTON, J. SATSANGI, Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, 2008, 27, 7
  196. You have free access to this content196
    Tuan V. NGUYEN, Mapping translational research into individualized prognosis of fracture risk, International Journal of Rheumatic Diseases, 2008, 11, 4
  197. 197
    L. M. Byrd, C. R. Shiach, C. R. M. Hay, T. A. Johnston, Osteopenic fractures in pregnancy: Is low molecular weight heparin (LMWH) implicated?, Journal of Obstetrics & Gynaecology, 2008, 28, 5, 539

    CrossRef

  198. 198
    Niklas Rye Jørgensen, Peter Schwarz, Osteoporosis in chronic obstructive pulmonary disease patients, Current Opinion in Pulmonary Medicine, 2008, 14, 2, 122

    CrossRef

  199. 199
    Jean M. Kaufman, Stefan Goemaere, Osteoporosis in men, Best Practice & Research Clinical Endocrinology & Metabolism, 2008, 22, 5, 787

    CrossRef

  200. 200
    B. Espina Riera, J. González-Macías, Patogenia de la osteoporosis esteroidea, Revista Española de Enfermedades Metabólicas Óseas, 2008, 17, 3, 44

    CrossRef

  201. 201
    P. Hadji, J. -J. Body, M. S. Aapro, A. Brufsky, R. E. Coleman, T. Guise, A. Lipton, M. Tubiana-Hulin, Practical guidance for the management of aromatase inhibitor-associated bone loss, Annals of Oncology, 2008, 19, 8, 1407

    CrossRef

  202. 202
    Marc-Antoine Krieg, Reinhart Barkmann, Stefano Gonnelli, Alison Stewart, Douglas C. Bauer, Luis Del Rio Barquero, Jonathan J. Kaufman, Roman Lorenc, Paul D. Miller, Wojciech P. Olszynski, Catalina Poiana, Anne-Marie Schott, E. Michael Lewiecki, Didier Hans, Quantitative Ultrasound in the Management of Osteoporosis: The 2007 ISCD Official Positions, Journal of Clinical Densitometry, 2008, 11, 1, 163

    CrossRef

  203. 203
    J. Compston, D. M. Reid, J. Boisdron, M.-L. Brandi, N. Burlet, D. Cahall, P. D. Delmas, W. Dere, J.-P. Devogelaer, L. A. Fitzpatrick, B. Flamion, N. Goel, S. Korte, A. Laslop, B. Mitlak, S. Ormarsdottir, J. Ringe, R. Rizzoli, Y. Tsouderos, T. Van Staa, J.-Y. Reginster, Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science, Osteoporosis International, 2008, 19, 9, 1247

    CrossRef

  204. 204
    B.L. Clarke, Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis, Yearbook of Endocrinology, 2008, 2008, 228

    CrossRef

  205. 205
    John A. Kanis, Judith Adams, Fred Borgström, Cyrus Cooper, Bengt Jönsson, Danielle Preedy, Peter Selby, Juliet Compston, The cost-effectiveness of alendronate in the management of osteoporosis, Bone, 2008, 42, 1, 4

    CrossRef

  206. 206
    Allyson K McDonough, Jeffrey R Curtis, Kenneth G Saag, The epidemiology of glucocorticoid-associated adverse events, Current Opinion in Rheumatology, 2008, 20, 2, 131

    CrossRef

  207. 207
    Lisa M. Lix, Marina S. Yogendran, William D. Leslie, Souradet Y. Shaw, Richard Baumgartner, Christopher Bowman, Colleen Metge, Abba Gumel, Janet Hux, Robert C. James, Using multiple data features improved the validity of osteoporosis case ascertainment from administrative databases, Journal of Clinical Epidemiology, 2008, 61, 12, 1250

    CrossRef

  208. 208
    John T. Schousboe, Tamara Vokes, Susan B. Broy, Lynne Ferrar, Fergus McKiernan, Christian Roux, Neil Binkley, Vertebral Fracture Assessment: The 2007 ISCD Official Positions, Journal of Clinical Densitometry, 2008, 11, 1, 92

    CrossRef

  209. 209
    Stuart L. Silverman, Principles of Bone Biology, 2008,

    CrossRef

  210. 210
    Glen M. Blake, Ignac Fogelman, Principles of Bone Biology, 2008,

    CrossRef

  211. 211
    Chad L. Deal, Absolute fracture risk, Current Rheumatology Reports, 2007, 9, 1, 66

    CrossRef

  212. 212
    Anthony D Woolf, An update on glucocorticoid-induced osteoporosis, Current Opinion in Internal Medicine, 2007, 6, 5, 544

    CrossRef

  213. 213
    William D. Leslie, William A. Anderson, Colleen J. Metge, Lori-Jean Manness, Clinical risk factors for fracture in postmenopausal Canadian women: A population-based prevalence study, Bone, 2007, 40, 4, 991

    CrossRef

  214. 214
    L. Fardet, A. Flahault, A. Kettaneh, K.P. Tiev, T. Généreau, C. Tolédano, C. Lebbé, J. Cabane, Corticosteroid-induced clinical adverse events: frequency, risk factors and patient’s opinion, British Journal of Dermatology, 2007, 157, 1
  215. 215
    Patricia Dargent-Molina, Claude-Laurent Benhamou, Bernard Cortet, Bruno Sutter, Thierry Thomas, Devising global strategies for fracture-risk evaluation, Joint Bone Spine, 2007, 74, 3, 240

    CrossRef

  216. 216
    Bernard Bannwarth, Drug-Induced Musculoskeletal Disorders, Drug Safety, 2007, 30, 1, 27

    CrossRef

  217. 217
    Arnulf Langhammer, Siri Forsmo, Solfrid Lilleeng, Roar Johnsen, Leif Bjermer, Effect of inhaled corticosteroids on forearm bone mineral density: The HUNT Study, Norway, Respiratory Medicine, 2007, 101, 8, 1744

    CrossRef

  218. 218
    Jun Iwamoto, Tsuyoshi Takeda, Yoshihiro Sato, Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis – usefulness of alendronate and risedronate, Expert Opinion on Pharmacotherapy, 2007, 8, 16, 2743

    CrossRef

  219. 219
    Claude-Laurent Benhamou, Effects of osteoporosis medications on bone quality, Joint Bone Spine, 2007, 74, 1, 39

    CrossRef

  220. 220
    Claude-Laurent Benhamou, Effets des traitements de l'ostéoporose sur la qualité osseuse, Revue du Rhumatisme, 2007, 74, 1, 43

    CrossRef

  221. 221
    Juliet E. Compston, Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis, Current Rheumatology Reports, 2007, 9, 1, 78

    CrossRef

  222. 222
    Javier P. Gisbert, Fernando Gomollón, Errores frecuentes en el manejo del paciente ambulatorio con enfermedad inflamatoria intestinal, Gastroenterología y Hepatología, 2007, 30, 8, 469

    CrossRef

  223. 223
    Frank De Vries, Madelon Bracke, Hubert G. M. Leufkens, Jan-Willem J. Lammers, Cyrus Cooper, Tjeerd P. Van Staa, Fracture risk with intermittent high-dose oral glucocorticoid therapy, Arthritis & Rheumatism, 2007, 56, 1
  224. 224
    Karen Koenig Berris, Anita Lopes Repp, Michael Kleerekoper, Glucocorticoid-induced osteoporosis, Current Opinion in Endocrinology, Diabetes and Obesity, 2007, 14, 6, 446

    CrossRef

  225. 225
    Božidar Čurković, Glucocorticoid-Induced Osteoporosis, Archives of Industrial Hygiene and Toxicology, 2007, 58, 1

    CrossRef

  226. 226
    U. Lange, U. Müller-Ladner, Glukokortikoid-induzierte Osteoporose, Zeitschrift für Rheumatologie, 2007, 66, 2, 129

    CrossRef

  227. 227
    Ann-Charlott Söderpalm, Per Magnusson, Anne-Christine Åhlander, Jón Karlsson, Anna-Karin Kroksmark, Már Tulinius, Diana Swolin-Eide, Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy, Neuromuscular Disorders, 2007, 17, 11-12, 919

    CrossRef

  228. 228
    María Pilar Aguado Acín, Osteoporosis inducida por glucocorticoides: ¿qué hay de nuevo?, Reumatología Clínica, 2007, 3, S3

    CrossRef

  229. 229
    Alexandra Papaioannou, Courtney C Kennedy, Lisa Dolovich, Elaine Lau, Jonathan D Adachi, Patient Adherence to Osteoporosis Medications, Drugs & Aging, 2007, 24, 1, 37

    CrossRef

  230. 230
    R. Patel, G. M. Blake, I. Fogelman, Peripheral and Central Measurements of Bone Mineral Density Are Equally Strongly Associated with Clinical Risk Factors for Osteoporosis, Calcified Tissue International, 2007, 80, 2, 89

    CrossRef

  231. 231
    S. Grunenwald, Prévention et traitement de l'ostéoporose cortico-induite, Annales d'Endocrinologie, 2007, 68, 1, 74

    CrossRef

  232. 232
    Katsumitsu Arai, Makiko Hoshino, Takehiro Murai, Junichi Fujisawa, Naoki Kondo, Takahiro Netsu, Hiroshige Sano, Naoto Endo, Proximal femoral fracture in patients with rheumatoid arthritis, Modern Rheumatology, 2007, 17, 4, 317

    CrossRef

  233. 233
    Katsumitsu Arai, Makiko Hoshino, Takehiro Murai, Junichi Fujisawa, Naoki Kondo, Takahiro Netsu, Hiroshige Sano, Naoto Endo, Proximal femoral fracture in patients with rheumatoid arthritis, Modern Rheumatology, 2007, 17, 4, 317

    CrossRef

  234. 234
    Jennifer Grossman, Catherine H. MacLean, Quality Indicators for the Care of Osteoporosis in Vulnerable Elders, Journal of the American Geriatrics Society, 2007, 55,
  235. 235
    M. Rossini, O. Viapiana, A. Del Marco, F. de Terlizzi, D. Gatti, S. Adami, Quantitative Ultrasound in Adults with Cystic Fibrosis: Correlation with Bone Mineral Density and Risk of Vertebral Fractures, Calcified Tissue International, 2007, 80, 1, 44

    CrossRef

  236. 236
    Kerry Siminoski, William D. Leslie, Heather Frame, Anthony Hodsman, Robert G. Josse, Aliya Khan, Brian C. Lentle, Jacques Levesque, David J. Lyons, Giuseppe Tarulli, Jacques P. Brown, Recommendations for Bone Mineral Density Reporting in Canada: A Shift to Absolute Fracture Risk Assessment, Journal of Clinical Densitometry, 2007, 10, 2, 120

    CrossRef

  237. 237
    Tamara J. Vokes, Daniel L. Gillen, Ann T. Pham, Jeanne M. Lovett, Risk Factors for Prevalent Vertebral Fractures in Black and White Female Densitometry Patients, Journal of Clinical Densitometry, 2007, 10, 1, 1

    CrossRef

  238. 238
    Kenneth G. Saag, Elizabeth Shane, Steven Boonen, Fernando Marín, David W. Donley, Kathleen A. Taylor, Gail P. Dalsky, Robert Marcus, Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis, New England Journal of Medicine, 2007, 357, 20, 2028

    CrossRef

  239. 239
    Peter M. Wayne, Douglas P. Kiel, David E. Krebs, Roger B. Davis, Jacqueline Savetsky-German, Maureen Connelly, Julie E. Buring, The Effects of Tai Chi on Bone Mineral Density in Postmenopausal Women: A Systematic Review, Archives of Physical Medicine and Rehabilitation, 2007, 88, 5, 673

    CrossRef

  240. 240
    N.R. Jørgensen, P. Schwarz, I. Holme, B.M. Henriksen, L.J. Petersen, V. Backer, The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease—A cross sectional study, Respiratory Medicine, 2007, 101, 1, 177

    CrossRef

  241. 241
    J. A. Kanis, A. Oden, O. Johnell, H. Johansson, C. De Laet, J. Brown, P. Burckhardt, C. Cooper, C. Christiansen, S. Cummings, J. A. Eisman, S. Fujiwara, C. Glüer, D. Goltzman, D. Hans, M.-A. Krieg, A. La Croix, E. McCloskey, D. Mellstrom, L. J. Melton, H. Pols, J. Reeve, K. Sanders, A-M. Schott, A. Silman, D. Torgerson, T. van Staa, N. B. Watts, N. Yoshimura, The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women, Osteoporosis International, 2007, 18, 8, 1033

    CrossRef

  242. 242
    F. De Vries, S. Pouwels, J. W. J. Lammers, H. G. M. Leufkens, M. Bracke, C. Cooper, T. P. Van Staa, Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case–control study, Journal of Internal Medicine, 2007, 261, 2
  243. 243
    Patricia Dargent-Molina, Claude-Laurent Benhamou, Bernard Cortet, Bruno Sutter, Thierry Thomas, Vers une évaluation globale du risque fracturaire, Revue du Rhumatisme, 2007, 74, 5, 455

    CrossRef

  244. 244
    William D. Leslie, A Patient With Autoimmune Liver Disease on Steroids: Screening and Treatment of Bone Disease, Clinical Gastroenterology and Hepatology, 2006, 4, 12, 1440

    CrossRef

  245. 245
    William D. Leslie, Robert A. Adler, Ghada El-Hajj Fuleihan, Anthony Hodsman, David L. Kendler, Michael McClung, Paul D. Miller, Nelson B. Watts, Application of the 1994 WHO Classification to Populations Other Than Postmenopausal Caucasian Women: The 2005 ISCD Official Positions, Journal of Clinical Densitometry, 2006, 9, 1, 22

    CrossRef

  246. 246
    H. Kaji, T. Tobimatsu, J. Naito, M.-F. Iu, M. Yamauchi, T. Sugimoto, K. Chihara, Body composition and vertebral fracture risk in female patients treated with glucocorticoid, Osteoporosis International, 2006, 17, 4, 627

    CrossRef

  247. 247
    Aliya Khan, Zeba Syed, Bone mineral density assessment in premenopausal women, Women's Health, 2006, 2, 4, 639

    CrossRef

  248. 248
    S. BOONEN, D. VANDERSCHUEREN, P. HAENTJENS, P. LIPS, Calcium and vitamin D in the prevention and treatment of osteoporosis – a clinical update, Journal of Internal Medicine, 2006, 259, 6
  249. 249
    J. R. Curtis, A. O. Westfall, J. J. Allison, A. Freeman, K. G. Saag, Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users, Osteoporosis International, 2006, 17, 8, 1268

    CrossRef

  250. 250
    D.A. Pate, O.D. Messina, Desarrollo y validaci n de un cuestionario predictivo de osteoporosis (OPARG score), Revista Española de Enfermedades Metabólicas Óseas, 2006, 15, 3, 39

    CrossRef

  251. 251
    Jean-Pierre Devogelaer, Stefan Goemaere, Steven Boonen, Jean-Jacques Body, Jean-Marc Kaufman, Jean-Yves Reginster, Serge Rozenberg, Yves Boutsen, Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club, Osteoporosis International, 2006, 17, 1, 8

    CrossRef

  252. 252
    Carlos de Juan Asenjo, Fractura vertebral osteoporótica, FMC - Formación Médica Continuada en Atención Primaria, 2006, 13, 10, 598

    CrossRef

  253. 253
    Courtney C Kennedy, Alexandra Papaioannou, Jonathan D Adachi, Glucocorticoid-induced osteoporosis, Women's Health, 2006, 2, 1, 65

    CrossRef

  254. 254
    Pietra Pennisi, Andrea Trombetti, Ren?? Rizzoli, Glucocorticoid-induced Osteoporosis and Its Treatment, Clinical Orthopaedics and Related Research, 2006, 443, :, 39

    CrossRef

  255. 255
    Gherardo Mazziotti, Alberto Angeli, John P. Bilezikian, Ernesto Canalis, Andrea Giustina, Glucocorticoid-induced osteoporosis: an update, Trends in Endocrinology & Metabolism, 2006, 17, 4, 144

    CrossRef

  256. 256
    Jean-Pierre Devogelaer, Glucocorticoid-Induced Osteoporosis: Mechanisms and Therapeutic Approach, Rheumatic Disease Clinics of North America, 2006, 32, 4, 733

    CrossRef

  257. 257
    Alberto Angeli, Giuseppe Guglielmi, Andrea Dovio, Giovanni Capelli, Daniela de Feo, Sandro Giannini, Ruben Giorgino, Luigi Moro, Andrea Giustina, High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: A cross-sectional outpatient study, Bone, 2006, 39, 2, 253

    CrossRef

  258. 258
    Charles N. Bernstein, Inflammatory bowel diseases as secondary causes of osteoporosis, Current Osteoporosis Reports, 2006, 4, 3, 116

    CrossRef

  259. 259
    Charles N. Bernstein, Inflammatory bowel diseases as secondary causes of osteoporosis, Current Osteoporosis Reports, 2006, 4, 3, 116

    CrossRef

  260. 260
    R. Dreher, F. Buttgereit, W. Demary, B. Görtz, G. Hein, P. Kern, A. Schulz, Insuffizienzfrakturen in der Rheumatologie, Zeitschrift für Rheumatologie, 2006, 65, 5, 417

    CrossRef

  261. 261
    &NA;, Management of osteoporosis in postmenopausal women, Menopause, 2006, 13, 3, 340

    CrossRef

  262. 262
    Angela Lamb, Victoria Werth, Osteoporosis in Health and Disease: A Dermatologist's Perspective, Dermatologic Clinics, 2006, 24, 2, 241

    CrossRef

  263. 263
    Pietra Pennisi, Andrea Trombetti, Emiliano Giostra, Gilles Mentha, René Rizzoli, Carmelo E. Fiore, Pamidronate and osteoporosis prevention in liver transplant recipients, Rheumatology International, 2006, 27, 3, 251

    CrossRef

  264. 264
    Claire Durosier, Didier Hans, Marc-Antoine Krieg, Anne-Marie Schott, Prediction and Discrimination of Osteoporotic Hip Fracture in Postmenopausal Women, Journal of Clinical Densitometry, 2006, 9, 4, 475

    CrossRef

  265. 265
    Gary R. Lichtenstein, Bruce E. Sands, Michael Pazianas, Prevention and treatment of osteoporosis in inflammatory bowel disease, Inflammatory Bowel Diseases, 2006, 12, 8
  266. 266
    Margaret Gourlay, Nora Franceschini, Yevgeniy Sheyn, Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures, Clinical Rheumatology, 2006, 26, 2, 144

    CrossRef

  267. 267
    C. Roux, Prévention et traitement de l’ostéoporose cortico-induite, Annales d'Endocrinologie, 2006, 67, 2, 162

    CrossRef

  268. 268
    E Michael Lewiecki, Prevention of osteoporotic fractures, Aging Health, 2006, 2, 4, 649

    CrossRef

  269. 269
    Marc C. Hochberg, Recommendations for Measurement of Bone Mineral Density and Identifying Persons to be Treated for Osteoporosis, Rheumatic Disease Clinics of North America, 2006, 32, 4, 681

    CrossRef

  270. 270
    Katsumitsu Arai, Tadamasa Hanyu, Hiroya Sugitani, Takehiro Murai, Junichi Fujisawa, Kiyoshi Nakazono, Naoki Kondo, Naoto Endo, Risk factors for vertebral fracture in menopausal or postmenopausal Japanese women with rheumatoid arthritis: a cross-sectional and longitudinal study, Journal of Bone and Mineral Metabolism, 2006, 24, 2, 118

    CrossRef

  271. 271
    Stuart L. Silverman, Selecting patients for osteoporosis therapy, Current Osteoporosis Reports, 2006, 4, 3, 91

    CrossRef

  272. 272
    Stuart L. Silverman, Selecting patients for osteoporosis therapy, Current Osteoporosis Reports, 2006, 4, 3, 91

    CrossRef

  273. 273
    Aliya A. Khan, David A. Hanley, John P. Bilezikian, Neil Binkley, Jacques P. Brown, Anthony B. Hodsman, Robert G. Josse, David L. Kendler, E. Michael Lewiecki, Paul D. Miller, Wojciech P. Olszynski, Steven M. Petak, Zeba A. Syed, Diane Theriault, Nelson B. Watts, Standards for Performing DXA in Individuals With Secondary Causes of Osteoporosis, Journal of Clinical Densitometry, 2006, 9, 1, 47

    CrossRef

  274. 274
    T. P. van Staa, The Pathogenesis, Epidemiology and Management of Glucocorticoid-Induced Osteoporosis, Calcified Tissue International, 2006, 79, 3, 129

    CrossRef

  275. 275
    Miriam Delaney, Understanding Bone Strength, The Endocrinologist, 2006, 16, 2, 79

    CrossRef

  276. 276
    Jane ZOCHLING, Peter NASH, John RIORDAN, Philip N. SAMBROOK, Use of corticosteroids and bone-active medications in clinical practice, APLAR Journal of Rheumatology, 2006, 9, 1
  277. 277
    E. von Scheven, C.M. Gordon, D. Wypij, M. Wertz, K.T. Gallagher, L. Bachrach, Variable Deficits of Bone Mineral Despite Chronic Glucocorticoid Therapy in Pediatric Patients with Inflammatory Diseases: Α Glaser Pediatric Research Network Study, Journal of Pediatric Endocrinology and Metabolism, 2006, 19, 6

    CrossRef

  278. 278
    Claude-Laurent Benhamou, Patricia Dargent, Vers un index de facteurs de risque de fracture ostéoporotique, Revue du Rhumatisme, 2006, 73, 8, 807

    CrossRef

  279. 279
    Tamara Vokes, Donald Bachman, Sanford Baim, Neil Binkley, Susan Broy, Lynne Ferrar, E. Michael Lewiecki, Bradford Richmond, John Schousboe, Vertebral Fracture Assessment: The 2005 ISCD Official Positions, Journal of Clinical Densitometry, 2006, 9, 1, 37

    CrossRef

  280. 280
    S. Kaptoge, G. Armbrecht, D. Felsenberg, M. Lunt, K. Weber, S. Boonen, I. Jajic, J. J. Stepan, D. Banzer, W. Reisinger, J. Janott, G. Kragl, C. Scheidt-Nave, B. Felsch, C. Matthis, H. H. Raspe, G. Lyritis, G Póor, R. Nuti, T. Miazgowski, K. Hoszowski, J. Bruges Armas, A. Lopes Vaz, L. I. Benevolenskaya, P. Masaryk, J. B. Cannata, O. Johnell, D. M. Reid, A. Bhalla, A. D. Woolf, C. J. Todd, C. Cooper, R. Eastell, J. A. Kanis, T. W. O’Neill, A. J. Silman, J. Reeve, Whom to treat? The contribution of vertebral X-rays to risk-based algorithms for fracture prediction. Results from the European Prospective Osteoporosis Study, Osteoporosis International, 2006, 17, 9, 1369

    CrossRef

  281. 281
    Peter Vestergaard, Antiresorptive Therapy for the Prevention of Postmenopausal Osteoporosis, Treatments in Endocrinology, 2005, 4, 5, 263

    CrossRef

  282. 282
    Robert S Weinstein, Stavros C Manolagas, Apoptosis in glucocorticoid-induced bone disease, Current Opinion in Internal Medicine, 2005, 4, 4, 337

    CrossRef

  283. 283
    John A. Kanis, Frederik Borgstrom, Chris De Laet, Helena Johansson, Olof Johnell, Bengt Jonsson, Anders Oden, Niklas Zethraeus, Bruce Pfleger, Nikolai Khaltaev, Assessment of fracture risk, Osteoporosis International, 2005, 16, 6, 581

    CrossRef

  284. 284
    M. van der Klift, C.D.E. de Laet, H.A.P. Pols, Assessment of fracture risk: Who should be treated for osteoporosis?, Best Practice & Research Clinical Rheumatology, 2005, 19, 6, 937

    CrossRef

  285. 285
    Elaine Dennison, Zoe Cole, Cyrus Cooper, Diagnosis and epidemiology of osteoporosis, Current Opinion in Rheumatology, 2005, 17, 4, 456

    CrossRef

  286. 286
    Jane A. Cauley, Robin L. Fullman, Katie L. Stone, Joseph M. Zmuda, Douglas C. Bauer, Elizabeth Barrett-Connor, Kristine Ensrud, Edith M. C. Lau, Eric S. Orwoll, Factors associated with the lumbar spine and proximal femur bone mineral density in older men, Osteoporosis International, 2005, 16, 12, 1525

    CrossRef

  287. 287
    Vibke Lilleby, Gunhild Lien, Kathrine Frey Frøslie, Margaretha Haugen, Berit Flatø, ØYstein Førre, Frequency of osteopenia in children and young adults with childhood-onset systemic lupus erythematosus, Arthritis & Rheumatism, 2005, 52, 7
  288. 288
    Nabil S. Enattah, Raimo Sulkava, Pirjo Halonen, Kimmo Kontula, Irma Järvelä, Genetic Variant of Lactase-Persistent C/T-13910 Is Associated with Bone Fractures in Very Old Age, Journal of the American Geriatrics Society, 2005, 53, 1
  289. 289
    Jonathan D. Adachi, Alexandra Papaioannou, In whom and how to prevent glucocorticoid-induced osteoporosis, Best Practice & Research Clinical Rheumatology, 2005, 19, 6, 1039

    CrossRef

  290. 290
    S. Boonen, D. Vanderschueren, W. Lauriks, J. P. Devogelaer, Inhaled corticosteroids and risk of osteoporosis in asthma - reply, Journal of Internal Medicine, 2005, 258, 3
  291. 291
    Jeffrey R. Curtis, Andrew O. Westfall, Jeroan J. Allison, Angela Becker, Linda Casebeer, Allison Freeman, Claire M. Spettell, Norman W. Weissman, Scott Wilke, Kenneth G. Saag, Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients, Arthritis & Rheumatism, 2005, 52, 8
  292. 292
    C. Scheidt-Nave, A. Starker, Osteoporoseprävalenz und assoziierte Versorgungsmuster bei Frauen im Alter ab 45 Jahren in Deutschland, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2005, 48, 12, 1338

    CrossRef

  293. 293
    Joseph L. Shaker, Barbara P. Lukert, Osteoporosis Associated with Excess Glucocorticoids, Endocrinology and Metabolism Clinics of North America, 2005, 34, 2, 341

    CrossRef

  294. 294
    Chin Lee, Rosalind Ramsey-Goldman, Osteoporosis in Systemic Lupus Erythematosus Mechanisms, Rheumatic Disease Clinics of North America, 2005, 31, 2, 363

    CrossRef

  295. 295
    Jun Iwamoto, Tsuyoshi Takeda, Yoshihiro Sato, Prevention and Treatment of Corticosteroid-Induced Osteoporosis, Yonsei Medical Journal, 2005, 46, 4, 456

    CrossRef

  296. 296
    Eric C. Abadie, Jean-Pierre Devogealer, Johann D. Ringe, Dominique J. Ethgen, Gilles M. Bouvenot, Gottfried Kreutz, Andrea Laslop, John J. Orloff, Philippe M. Vanderauwera, Pierre D. Delmas, Willard H. Dere, Jaime Branco, Roy D. Altman, Bernard P. Avouac, Charles J. Menkes, Luc Vanhaelst, Bruce H. Mitlak, Yannis Tsouderos, Jean-Yves L. Reginster, Recommendations for the Registration of Agents to be Used in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: Updated Recommendations from the Group for the Respect of Ethics and Excellence in Science, Seminars in Arthritis and Rheumatism, 2005, 35, 1, 1

    CrossRef

  297. 297
    S.R. Mastaglia, A. Bagur, G. Goldstein, M.S. Parisi, B. Oliveri, Resultados de una campaña de detección de población en riesgo para desarrollar osteoporosis y fracturas, Revista Española de Enfermedades Metabólicas Óseas, 2005, 14, 4, 61

    CrossRef

  298. 298
    Michael R. McClung, The relationship between bone mineral density and fracture risk, Current Osteoporosis Reports, 2005, 3, 2, 57

    CrossRef

  299. 299
    Charles N Bernstein, William D Leslie, Therapy Insight: osteoporosis in inflammatory bowel disease—advances and retreats, Nature Clinical Practice Gastroenterology & Hepatology, 2005, 2, 5, 232

    CrossRef

  300. 300
    Ph. Orcel, Glucocorticoïdes et os, Annales d'Endocrinologie, 2004, 65, 6, 492

    CrossRef

  301. 301
    Akira Onishi, Akira Sato, Masahiro Iwasaku, Toshi A Furukawa, Human parathyroid hormone for preventing and treating glucocorticoid-induced osteoporosis, The Cochrane Library,
  302. 302
    Ann Cranney, Alaa Rostom, Catherine Dubé, Rachid Mohamed, Peter Tugwell, George Wells, John WD McDonald, Metabolic Bone Disease in Gastrointestinal Disorders,
  303. 303
    Celeste J. Hamilton, Sophie A. Jamal, Earl R. Bogoch, Osteoporosis and Metabolic Disorders,